Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

52.81 -0.53 (-0.99%)

Streaming Delayed Price Updated: 10:50 AM EDT, May 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

37 38 Next >

Biotech Sector Working Fast to Combat Alzheimer’s Disease Cases That are Set to Explode

March 15, 2023

FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 15, 2023 – USA News Group – According to a 2022 study of more than 6 million patients 65 and older, the risk factor for...

Via FinancialNewsMedia

FDA Advisory Committee Votes in Favor of the Clinical Benefit of Genentech's Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma

March 09, 2023

From Genentech

Via Business Wire

FDA Casts Doubts Over Roche's Polivy Label Expansion For Untreated Lymphoma Setting ↗

March 09, 2023

Via Benzinga

Roche Introduces Test To Detect Contagious XBB.1.5 Omicron Sub-Variant ↗

January 26, 2023

Via Benzinga

The Top 7 Growth Stocks in Biotech ↗

March 03, 2023

The biotech sector always houses a great selection of growth stocks that can grow rapidly and reward investors over the long-term.

Via InvestorPlace

Roche, Exelixis Report Second Flop Out Of Three Trials Evaluating Cabozantinib/Atezolizumab Combo ↗

March 03, 2023

Via Benzinga

Why Sarepta Therapeutics' Shares Rose 23.4% This Week ↗

March 02, 2023

The company's latest Duchenne muscular dystrophy gene therapy may have an accelerated approval.

Via The Motley Fool

3 Best Growth Stocks to Buy In March ↗

March 02, 2023

These three red-hot growth stocks have more room to run.

Via The Motley Fool

Blueprint Medicines Highlights Detailed Data From Lead Product In Blood Cancer Patients ↗

February 27, 2023

Via Benzinga

Roche Decides To Terminate Cancer Treatment Pact With Blueprint Medicines ↗

February 23, 2023

Via Benzinga

Infinity Pharmaceuticals Announce Merger Agreement With MEI Pharma, Share Plunge ↗

February 23, 2023

Via Benzinga

Apellis Surges To Four-Month High — Sending Rival Iveric Tumbling — On A First-Ever Approval ↗

February 21, 2023

Apellis is soon to launch its newest drug, Syfovre, for geographic atrophy patients.

Via Investor's Business Daily

Biogen Beats Q4 Earnings & Sales Estimates, Stock Up ↗

February 15, 2023

Biogen reported fourth-quarter 2022 adjusted earnings per share (EPS) of $4.05.

Via Talk Markets

New Data Shows Roche's Vabysmo Improves Vision, Retinal Fluid In Retinal Disorder ↗

February 10, 2023

Via Benzinga

New Phase III Data Show Genentech’s Vabysmo Rapidly Improved Vision and Reduced Retinal Fluid in People With Retinal Vein Occlusion (RVO)

February 10, 2023

From Genentech

Via Business Wire

Roche Touts Positive Crovalimab Data From Late-Stage Study In Rare Blood Condition ↗

February 07, 2023

Via Benzinga

Genentech Announces Positive Data From Global Phase III Program for Crovalimab in PNH, a Rare, Life-Threatening Blood Condition

February 07, 2023

From Genentech

Via Business Wire

Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric ↗

February 02, 2023

The company that remains still has a large pipeline of non-migraine assets.

Via Investor's Business Daily

Roche Flags Lower 2023 Sales On Declining Demand For COVID-19 Treatment, Diagnostics ↗

February 02, 2023

Via Benzinga

Genentech's Tecentriq Plus Avastin Combo Cuts Risk of Cancer Returning In Early-Stage Liver Cancer ↗

January 19, 2023

Via Benzinga

Genentech’s Tecentriq Plus Avastin Is the First Treatment Combination to Reduce the Risk of Cancer Returning in People With Certain Types of Early-Stage Liver Cancer in a Phase III Trial

January 19, 2023

From Genentech

Via Business Wire

Trading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group's Most Active List In December ↗

January 17, 2023

On December 14th, the Federal Reserve hiked its key interest rate by 50 basis points. This was the first deceleration in rate hike increases in 2022; between March and November 2022, the interest rate...

Via Benzinga

Europe Approves Xofluza, Roche's Revolutionary Influenza Antiviral with New Mechanism ↗

January 12, 2023

Via Benzinga

Biotech Giant Regeneron Hit As Eylea Gives Ground To Avastin ↗

January 09, 2023

Regeneron Pharmaceuticals says sales of linchpin Eylea drug have been negatively impacted rival drug Avastin. REGN stock plunged on the news.

Via Investor's Business Daily

Twitter Hackers Stole More Than 200M Emails, Delta Air Lines To Offer Free Wi-Fi, Bed Bath & Beyond's Bankruptcy Coming Sooner Than Expected: Top Stories Today ↗

January 06, 2023

Benzinga

Via Benzinga

Roche's Investigational Lymphoma Candidate Goes Under FDA Priority Review ↗

January 06, 2023

Via Benzinga

FDA Grants Priority Review to Genentech’s Bispecific Antibody Glofitamab for People With Relapsed or Refractory Large B-Cell Lymphoma

January 06, 2023

From Genentech

Via Business Wire

Can The No. 1 Pharma Stock, Merck, Continue Its Blazing Run In 2023? ↗

January 05, 2023

Merck has a number of efforts in the works to help avoid a Keytruda generics pitfall.

Via Investor's Business Daily

Better Large-Cap Buy: Roche Holding or Gilead Sciences Stock? ↗

January 02, 2023

Which of these companies is better able to replace declining COVID-19-related sales?

Via The Motley Fool

Big Health Care Stocks to Watch in the New Year

December 29, 2022

Here are three health care stocks to watch as the New Year begins. Two have a moderate Buy rating while one is a Hold, for now.

Via MarketBeat

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

37 38 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.